Neuberger Berman Group LLC Biomarin Pharmaceutical Inc Transaction History

Neuberger Berman Group LLC

$118 Billion
Q1 2024

A detailed history of Neuberger Berman Group LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Neuberger Berman Group LLC holds 465,730 shares of BMRN stock, worth $38.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

465,730

Holding current value

$38.3 Million

% of portfolio

0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $39 Million - $46.1 Million	465,730 New	465,730 $40.7 Million
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $8.24 Million - $10.6 Million	108,094 Added 44.92%	348,722 $33.6 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $3.41 Million - $3.78 Million	40,032 Added 19.96%	240,628 $21.3 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $4.03 Million - $4.67 Million	46,549 Added 30.22%	200,596 $17.4 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $1.31 Million - $1.76 Million	-14,975 Reduced 8.86%	154,047 $15 Million

Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $176,832 - $237,356	2,185 Added 1.31%	169,022 $17.5 Million
Q3 2022 Nov 15, 2022	BUY	$82.16 - $96.94 $11.4 Million - $13.5 Million	139,356 Added 507.1%	166,837 $14.1 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $17,298 - $21,017	-242 Reduced 0.87%	27,481 $2.28 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $368,725 - $460,113	-4,964 Reduced 15.19%	27,723 $1.95 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $390,300 - $497,779	5,442 Added 19.97%	32,687 $2.68 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $402,711 - $460,341	-5,386 Reduced 16.51%	27,245 $1.96 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $345,080 - $387,490	-4,570 Reduced 12.28%	32,631 $2.58 Million
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $103,949 - $126,149	1,391 Added 3.88%	37,201 $2.74 Million
Q4 2020 Feb 10, 2021	SELL	$72.61 - $90.2 $3.06 Million - $3.8 Million	-42,171 Reduced 54.08%	35,810 $3.12 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $527,813 - $962,284	-7,344 Reduced 8.61%	77,981 $5.93 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $9.4 Million - $14.7 Million	-118,187 Reduced 58.07%	85,325 $10.5 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $244,014 - $331,130	-3,419 Reduced 1.65%	203,512 $17.2 Million
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $1.68 Million - $2.26 Million	26,156 Added 14.47%	206,931 $17.5 Million
Q3 2019 Nov 13, 2019	SELL	$67.4 - $85.11 $49.6 Million - $62.6 Million	-735,538 Reduced 80.27%	180,775 $12.2 Million
Q2 2019 Aug 13, 2019	SELL	$80.35 - $93.9 $11.1 Million - $13 Million	-138,025 Reduced 13.09%	916,313 $78.5 Million
Q1 2019 May 13, 2019	SELL	$84.2 - $98.62 $18.1 Million - $21.1 Million	-214,426 Reduced 16.9%	1,054,338 $93.7 Million
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $2.87 Million - $3.79 Million	-35,754 Reduced 2.74%	1,268,764 $108 Million
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $10.9 Million - $12.3 Million	116,452 Added 9.8%	1,304,518 $126 Million
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $35.9 Million - $46.7 Million	471,829 Added 65.88%	1,188,066 $112 Million
Q1 2018 May 08, 2018	BUY	$77.67 - $92.63 $31.9 Million - $38.1 Million	411,140 Added 134.76%	716,237 $58.1 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $14.6 Million - $17.2 Million	181,192 Added 146.23%	305,097 $27.2 Million
Q3 2017 Nov 15, 2017	BUY	$80.6 - $94.95 $9.99 Million - $11.8 Million	123,905	123,905 $11.5 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Account

Neuberger Berman Group LLC Biomarin Pharmaceutical Inc Transaction History